- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 40/10 - Immunothérapie cellulaire caractérisée par le type de cellules
Détention brevets de la classe A61K 40/10
Brevets de cette classe: 208
Historique des publications depuis 10 ans
|
1
|
2
|
5
|
16
|
20
|
26
|
15
|
8
|
49
|
50
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Trustees of the University of Pennsylvania | 4432 |
6 |
| The Regents of the University of California | 20842 |
5 |
| Memorial Sloan-Kettering Cancer Center | 2056 |
5 |
| Regents of the University of Minnesota | 2797 |
5 |
| The Board of Trustees of the Leland Stanford Junior University | 6697 |
4 |
| FATE Therapeutics, Inc. | 235 |
4 |
| Marengo Therapeutics, Inc. | 96 |
4 |
| Wisconsin Alumni Research Foundation | 3903 |
3 |
| The Johns Hopkins University | 5922 |
3 |
| Purdue Research Foundation | 3941 |
3 |
| The Regents of the University of Colorado, a body corporate | 2835 |
3 |
| Iovance Biotherapeutics, Inc. | 406 |
3 |
| Moonshot Antibodies, LLC | 5 |
3 |
| Kelonia Therapeutics, Inc. | 51 |
3 |
| The Regents of the University of Michigan | 5023 |
2 |
| President and Fellows of Harvard College | 6110 |
2 |
| Vertex Pharmaceuticals Incorporated | 1575 |
2 |
| Assistance Publique - Hopitaux de Paris | 1058 |
2 |
| Cell Therapy Limited | 30 |
2 |
| The Children's Mercy Hospital | 86 |
2 |
| Autres propriétaires | 142 |